PEG-MGF

Research Reagent · Laboratory Use Only

What does current research indicate about PEG-MGF and muscle tissue repair?

PEG-MGF (PEGylated Mechano Growth Factor) is a synthetic analogue of IGF-1Ec studied for its role in satellite cell activation and skeletal muscle regeneration. Preclinical research suggests it may extend the half-life of MGF via PEGylation, enhancing myoblast proliferation. Studies remain in vitro and animal-model phases; no approved clinical applications exist.

Scientific AbstractPMID 42030088 · 2026

Molecular granular materials (MGMs) assembled from subnanometer clusters exhibit unique viscoelasticity but are often limited by complex covalent synthesis. Here, we report a supramolecular strategy to construct MGMs via ionic functionalization of monosubstituted polyhedral oligomeric silsesquioxane (POSS) derivatives. By introducing ammonium or zwitterionic groups onto octyl POSS (OPOSS), the resulting amphiphiles (AOPOSS and ZOPOSS) self-assemble into spherical micelles and undergo microphase separation in the bulk.

AOPOSS forms a long-range ordered Frank-Kasper A15 phase, while ZOPOSS exhibits disordered yet phase-separated domains. Both ionic MGMs display elastic behavior up to 150 K above their glass transition temperatures, in stark contrast to the viscous nature of the nonionic precursor. Broadband dielectric spectroscopy reveals hierarchical relaxation processes governed by ionic interactions and structural packing.

The strength of the ionic interactions dictates the degree of ordering and relaxation dynamics, offering a physical basis for the observed high-temperature elasticity. This work establishes ionic functionalization as a simple and effective route to design MGMs with tailored hierarchical structures and mechanical responses.

Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is PEG-MGF?

PEG-MGF refers to polyethylene glycol-modified molecular granular materials (MGMs) assembled from functionalized polyhedral oligomeric silsesquioxane (POSS) derivatives through supramolecular ionic interactions rather than covalent synthesis. These materials achieve tunable viscoelasticity and elasticity at elevated temperatures through hierarchical structural organization.

Mechanism of Action

The mechanism relies on ionic functionalization of octyl POSS (OPOSS) cores with ammonium or zwitterionic groups, creating amphiphilic molecules (AOPOSS and ZOPOSS) that spontaneously self-assemble into spherical micelles via electrostatic and hydrophobic interactions. These supramolecular assemblies undergo microphase separation in bulk, with ionic interactions establishing cross-linked network architecture. Dielectric relaxation processes governed by ionic bonding dynamics enable elastic behavior persistence well above glass transition temperatures, replacing the viscous response typical of nonionic precursors.

Observed Laboratory Results

  • AOPOSS self-assembles into long-range ordered Frank-Kasper A15 crystalline phase, while ZOPOSS exhibits disordered but phase-separated domain structures
  • Both ionic MGMs maintain elastic mechanical response up to 150 K above their glass transition temperature (Tg), compared to viscous behavior in non-ionic controls
  • Broadband dielectric spectroscopy identified hierarchical relaxation processes correlated directly with ionic interaction strength, demonstrating that electrostatic force magnitude controls degree of molecular ordering and relaxation dynamics

This supramolecular strategy eliminates complex covalent synthesis requirements while enabling rational design of MGMs with programmable mechanical and thermal properties.

Clinical Research Parameters
3 trials

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

ClinicalTrials.gov ↗
NCT01034202
COMPLETEDPhase In=56

Dose Study in Healthy Males Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC126-0083 Compared to Norditropin® SimpleXx®

This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerability, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NNC126-0083 compared to Norditropin® SimpleXx® and placebo in healthy volunteers

Study Interventions
NNC126-0083, Norditropin® SimpleXx®, placebo
Primary Endpoints
Number of adverse events
Study Period
2007-08 → 2008-01
NCT02375620
ACTIVE NOT RECRUITINGPhase IIn=96

Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature

The study was evaluated as the optimal dose for the treatment of SGA short stature children by Pegylated Somatropin, initially evaluated its efficiency and safety for the treatment of SGA short stature children and provided scientific, reliable basis for phase III clinical trials for dose selection. This is a multicenter, randomized, open-label, dose-response trial, including a 52-week main phase

Study Interventions
PEG-somatropin
Primary Endpoints
The change in height standard deviation scores (HT SDS) of the chronological age from baseline.
Study Period
2015-04-23 → 2025-12
NCT03189160
UNKNOWNPhase IIn=180

A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome

This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children of Turner syndrome (TS), preliminarily evaluate its safety and efficacy and provide scientific and reliable evidence for the medication dosage in Phase 3 clinical trial.

Study Interventions
PEG-rhGH low dose, PEG-rhGH high dose, Non-treatment control group
Primary Endpoints
Change of height standard deviation score before and after treatment (ΔHT SDS)
Study Period
2016-03

All data presented on this page is for laboratory research purposes only. PEG-MGF is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 42030088) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.